A Multicenter, Randomized, Double-Blind, Placebo-controlled, Parallel Group, Phase 3 Study to Evaluate the Efficacy and Safety of Dapagliflozin as an Add-on to Insulin Therapy in Subjects With Type 1 Diabetes Mellitus - Study Two
A Multicenter, Randomized, Double-Blind, Placebo-controlled, Parallel Group, Phase 3 Study to Evaluate the Efficacy and Safety of Dapagliflozin as an Add-on to Insulin Therapy in Subjects With Type 1 Diabetes Mellitus - Study Two
The purpose of this study is to determine if adding dapagliflozin to insulin is a safe and effective therapy to improve glycemic control in patients with type 1 diabetes.
Study Classification: Safety, Efficacy and Pharmacokinetics/dynamics
Inclusion Criteria:
Exclusion Criteria:
CABA, 1056, Argentina
Pohlheim, 35415, Germany
Aki-gun, 735-0021, Japan
Amagasaki-shi, 661-0002, Japan
Chitose-shi, 066-0032, Japan
Fukuyama-shi, 721-0927, Japan
Higashiosaka-shi, 577-0802, Japan
Ibusuki-shi, 891-0401, Japan
Kamakura-shi, 247-0056, Japan
Kashiwara-shi, 582-0005, Japan
Kitakyushu-shi, 807-0857, Japan
Koriyama-shi, 963-8851, Japan
Kurume-shi, 830-8543, Japan
Miura-shi, 238-0101, Japan
Obihiro-shi, 080-0016, Japan
Oyama-shi, 323-0022, Japan
Shibuya-ku, 150-0013, Japan
Shinjuku-ku, 169-0073, Japan
Ushiku-shi, 300-1207, Japan
Uwajima-shi, 798-8510, Japan